
Caribou Biosciences Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Caribou Biosciences Inc
Access all reports
Caribou Biosciences Inc. is a clinical-stage biopharmaceutical company at the forefront of genome editing technology. It focuses on developing genome-edited allogeneic cell therapies for the treatment of cancer and other devastating diseases. The company utilizes CRISPR-Cas9 technology to create precise, directed changes in the DNA of living cells, aiming to develop innovative therapies that can address unmet medical needs. Caribou's leading product candidates include allogeneic chimeric antigen receptor T (CAR-T) cell therapies for hematologic malignancies and solid tumors. This approach allows for the development of therapies that are not patient-specific but can be used as "off-the-shelf" treatments, potentially reducing time and cost compared to traditional autologous CAR-T therapies. The company is headquartered in Berkeley, CA, and its shares are listed on the NASDAQ.
Key slides for Caribou Biosciences Inc


Corporate Presentation
Caribou Biosciences Inc


Corporate Presentation
Caribou Biosciences Inc
Latest articles
)
Figma: Collaborative Design Tool Ready for IPO
Figma, the popular design platform, is preparing for a potential IPO in 2025 as it continues to reshape the future of collaborative design.
22 May 2025
)
Companies That Had Their IPO in 2024: Momentum Increasing
2024 marked a steady year for IPOs, driven by strong markets, AI momentum, and high-profile listings across industries and regions.
22 May 2025
)
The Rise and Fall of Wirecard
A look inside the Wirecard scandal, which took the company from the prestigious DAX 30 to insolvency through the largest accounting fraud in European history.
16 May 2025
Ticker symbol
CRBU
Country
🇺🇸 United States